CRISPR/Cas9-mediated gene editing was used to create a polyclonal population of A-549 cells with targeted disruption of the ADCY3 locus. The resulting polyclonal knockout cells contain a diverse array of edited alleles, collectively abolishing ADCY3 protein expression. This loss-of-function model avoids clonal artifacts, providing a robust tool for studying ADCY3-dependent processes in a cellular background that retains the heterogeneity of the parental lung adenocarcinoma line.
The parental A-549 cell line is an established human lung adenocarcinoma model derived from a primary lung carcinoma. A-549 cells exhibit adherent epithelial morphology and are widely applied in cancer biology, toxicology, and drug discovery due to their well-characterized growth characteristics and responsiveness to diverse stimuli. They express a broad repertoire of GPCRs and downstream signaling components, making them particularly suitable for investigating cAMP-mediated pathways and their roles in tumorigenesis and therapeutic resistance.
ADCY3 is a transmembrane adenylate cyclase that converts ATP into the second messenger cyclic AMP (cAMP) upon stimulation by Gs alpha-coupled receptors, calcium/calmodulin, or protein kinase C. Elevated cAMP levels activate protein kinase A (PKA) and exchange protein directly activated by cAMP (EPAC), which then phosphorylate the transcription factor CREB and gate cyclic nucleotide-gated ion channels. ADCY3 interacts with Gs alpha subunits, calmodulin, and A-kinase anchoring proteins (AKAPs) to organize localized signaling domains. This enzymatic activity is essential for olfactory transduction, glucose-stimulated insulin secretion from pancreatic ??-cells, and cAMP-dependent ciliary signaling in epithelial cells.
In the context of A-549 lung adenocarcinoma, ADCY3-mediated cAMP production modulates key cellular processes including proliferation, metabolic reprogramming, and metastatic behavior. Disruption of the ADCY3 gene eliminates the primary route of GPCR-triggered cAMP generation, allowing researchers to dissect the specific contributions of this cyclase to downstream signaling and gene expression. The polyclonal knockout design ensures a population-level view of ADCY3’s roles, mitigating the influence of individual clone-specific adaptations. This makes the model especially valuable for deciphering how cAMP dynamics influence lung cancer progression and drug susceptibility.
This knockout cell population is compatible with a range of experimental techniques, including western blotting to confirm ADCY3 loss, quantitative cAMP accumulation assays after agonist treatment, PKA activity measurements, and RT-qPCR profiling of CREB-regulated genes. Functional studies of proliferation, migration, and invasion can directly assess the impact of ADCY3 on tumor cell aggressiveness. Beyond cancer research, the model supports GPCR drug screening, metabolic disease studies on insulin secretion, and heterologous olfactory receptor investigations. For technical inquiries, please contact Ascent Research.
